Actionable news
0
All posts from Actionable news
Actionable news in KPTI: KARYOPHARM THERAPEUTICS Inc,

Karyopharm Therapeutics: Targeting Disease At The Nuclear Pore Corporate Presentation

The following excerpt is from the company's SEC filing.

NASDAQ: KPTI

Exhibit 99.1

©2015

Karyopharm Therapeutics, Inc.

Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation

Reform Act of 1995.

Unless

otherwise

noted,

interim

unaudited

reports.

Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results

to differ materially

from the companys current expectations. For example, there can be no guarantee that Selinexor or any other drug candidate Karyopharm is

developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharms drug

candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharms drug candidate portfolio will result

in stock price appreciation. In addition, even if Karyopharm receives marketing approval for selinexor or another drug candidate, there can be no

assurance that Karyopharm will be able to successfully commercialize that drug candidate. Managements expectations and, therefore, any

forward-looking statements in this presentation could also be affected by risks and uncertainties relating to a number of other factors, many of

which are beyond Karyopharms control, including the following: Karyopharms results of clinical trials and preclinical studies, including

subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the

U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review

bodies; Karyopharms ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash

requirements and expenditures; development of drug candidates by Karyopharms competitors for diseases for which Karyopharm is currently

developing its drug candidates; and Karyopharms ability to obtain, maintain and enforce patent and other intellectual property protection for

any drug candidates it is developing.

These and other risks, including those which may impact managements expectations, are described in greater detail under the heading "Risk

Factors" in Karyopharms Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, which is on file with the Securities and

Exchange Commission, and in subsequent filings filed by Karyopharm with the Securities and Exchange Commission.

Any forward-looking statements contained in this presentation are for informational purposes only and speak only as of the date hereof.

Other than as is required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a

result of new information, future events or otherwise.

Karyopharms website is http://www.karyopharm.com. Karyopharm regularly uses its website to post information regarding its business, drug

development programs and governance. Karyopharm encourages investors to use www.karyopharm.com, particularly the information in the

section entitled Investors, as a source of information about Karyopharm. References to www.karyopharm.com in this presentation are not

intended to, nor shall they be deemed to, incorporate information on www.karyopharm.com into this presentation by reference.

Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans and

commercialization for Karyopharms lead drug candidate, selinexor (KPT-330), including the timing of initiation of certain trials and of the

reporting of data from such trials, other drug product candidate development plans, and assumptions of management regarding strategic and

financial expectations and projections.

Novel mechanism

First in class

Oral, small molecule

Fully Owned

Topline data in lead

indications expected Q4 16

Tumor Suppressor Protein

(TSP) activation and

oncoprotein

reduction

Potentially relevant to

type of cancer

ongoing later stage Heme

ongoing Ph

2 Solid Tumor

>40 combination studies

ongoing or planned

Prepare to commercialize

selinexor in NA and

Western EU

Seek collaborators for other

geographies

New Drug

Class in

Oncology

Commercial

Strategy

Clinical

Development

Initial

single-agent, while developing SINE compounds as novel approaches to treat a variety of

diseases in areas of unmet medical need

Karyopharms wholly owned, lead SINE compound selinexor offers an entirely new approach to

cancer therapy that restores the ability of a cell to detect cancerous changes and commit suicide

©2015

Karyopharm: At the Nucleus of Cancer Care

Selinexor: SINE Compound with Broad Clinical Development Strategy

Oral Selinexor

Hematological

Malignancies

AML (SOPRA)

DLBCL (SADAL)

Richters

(SIRRT)

Multiple Myeloma (STOMP)

Sel+Pom+Dex; Sel+Bort+Dex;...


More